HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation

HIV Medicine

Volumn 7, Issue 5, 2006, Pages 294-298

  Boucher, S ^a   Recordon Pinson, P ^a   Ragnaud, J M ^a   Dupon, M ^a   Fleury, H ^a   Masquelier, Bernard ^a,b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

HIV 1 drug resistance; K65R; Nucleoside reverse transcriptase inhibitors; Tenofovir

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; DATA BASE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; UNIVERSITY HOSPITAL; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FRANCE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33744468847     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00379.x     Document Type: Article

References (22)

1. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002; 16: 1227-1235.
2. Schooley RT, Ruane P, Myers RA et al. Tenofovir DF in antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study. AIDS 2002; 16: 1257-1263.
3. Parikh U, Koontz D, Sluis-Cremer N et al. K65R: A multinucleoside resistance mutation of increasing prevalence exhibits bi-directional phenotypic antagonism with TAM. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 54].
4. White K, Margot N, Chen J et al. The HIV-1 K65R RT mutant utilizes a combination of decreased incorporation and decreased excision to evade NRTI. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 55].
5. Kagan RM, Merigan TC, Winters MA, Heseltine PN. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization. Antivir Ther 2004; 9: 827-828.
6. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of once daily abacavir, lamivudine and tenofovir DF, in treatment-naive HIV-infected patients. 2nd International AIDS Society Conference on Pathogenesis and Treatment. Paris, France, July 2003 [Abstract 553].
7. Gallant J, Rodriguez A, Weinberg W et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC. ESS30009 unplanned interim analysis. 43rd Interscience Conference on Microbial Agents and Chemotherapy. Chicago, IL, September 2003 [Abstract H-1722a].
8. Landman R, Peytavin G, Descamps D et al. Low genetic barrier to resistance is a possible cause of early virological failures in once-daily regimen of abacavir, lamivudine, and tenofovir: The Tonus study. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 52].
9. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 2004 [Abstract 51].
10. Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: Genotypic, phenotypic, and rebound analyses. J Acquir Immune Defic Syndr 2003; 33: 15-21.
11. Miller MD, Margot N, Lu B et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189: 837-846.
12. Masquelier B, Tamalet C, Montes B et al. Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients. Antiviral Ther 2004; 9: 315-323.
13. Violin M, Cozzi-Lepri A, Velleca R et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 2004; 18: 227-235.
14. McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK, Miller MD. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr 2004; 37: 1340-1350.
15. Masquelier B, Neau D, Boucher S et al. Twenty-four-week efficacy and resistance profile of a zidovudine/lamivudine/tenofovir DF combination therapy in antiretroviral-naive patients. Antiviral Ther 2005; 10: S22.
16. Parikh UM, Koontz DL, Chu CK, Schinazi RF, Mellors JW. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother 2005; 49: 1139-1144.
17. Parikh U, Sluis-Cremer N, Mellors J. Kinetic mechanism by which thymidine analog mutations antagonize K65R in HIV-1 reverse transcriptase inhibitors. Antiviral Ther 2005; 10: S95.
18. Delaunay C, Descamps D, Landman R et al. Dynamic of selection of the K65R and M184V/I mutations in patients enrolled in Tonus trial. Antiviral Ther 2004; 9: S171.
19. Roge BT, Katzenstein TL, Obel N et al. K65R with and without S68: A new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antiviral Ther 2003; 8: 173-182.
20. Delaugerre C, Roudiere L, Peytavin G, Rouzioux C, Viard JP, Chaix ML. Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF. J Clin Virol 2005; 32: 241-244.
21. Kagan RM, Ross L, Winters M, Merigan TC, Heseltine PN, Lewinsky M. Adefovir-associated HIV-1 RT mutation K70E in the age of tenofovir. Antiviral Ther 2005; 10: S103.
22. Ross L, Gerondelis P, Liao Q et al. Selection of the HIV-1 reverse transcriptase mutation K70E in antiretroviral-naive subjects treated with tenofovir/abacavir/lamivudine therapy. Antiviral Ther 2005; 10: S102.